Press Releases May 20, 2026 08:30 AM

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

IRADIMED CORPORATION executives to present at Goldman Sachs 47th Annual Global Healthcare Conference

By Ajmal Hussain IRMD

IRADIMED CORPORATION announced that its President and CEO Roger Susi, along with CFO Jack Glenn, will attend and present at the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026. The company is an innovative leader in MRI-compatible medical devices, including its patented MRidium® IV infusion pump systems and patient vital signs monitoring system designed for safe use during MRI procedures.

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
IRMD

Key Points

  • IRADIMED is attending a major healthcare investment conference, signaling active investor engagement.
  • The company specializes in MRI-compatible medical devices, uniquely offering non-magnetic IV infusion pump systems.
  • This event provides an opportunity for direct investor meetings, potentially increasing market visibility and confidence.

ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.

Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services. We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system specifically designed to be safe for use during MRI procedures. Our patented MRidium® MRI-compatible IV infusion pump systems and our 3880 MRI-compatible patient vital signs monitoring system are designed to enable accurate, safe, and dependable care before, during, and after MRI procedures. For more information, please visit www.iradimed.com. 

For more information, please visit www.iradimed.com.

Media Contact:
Jack Glenn
Chief Financial Officer
Iradimed Corporation
(407) 677-8022
[email protected]


Risks

  • The announcement is purely about presentation attendance, with no new product or financial updates, which may dampen immediate market impact.
  • As a niche medical device manufacturer, IRADIMED faces competitive and regulatory risks inherent to the healthcare sector.
  • Market reaction may depend on further developments or disclosures beyond the conference presentation.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026